One Of ASCOs Sleeper Hits: OGX-011 Cuts Provenges Death Rate In Half
OGX011 survival benefit an even better Hazard Ratio.
With the release of ASCO abstracts last night we saw additional data and statistical analyses from OGXIs Phase II trial. This was a randomized, controlled Phase II trial in prostate cancer with their lead compound OGX011, that had shown a 10.6 month survival advantage, including a [...]